Maher Masoud: Thank you, Erik. Good afternoon, everyone, thank you for joining MaxCyte, Inc.'s fourth quarter and full year 2025 earnings call. 2025 presented a challenging operating environment; it ...
MaxCyte, Inc. has announced preliminary financial results for the fourth quarter and full year of 2024, projecting core revenue between $8.3 million and $8.5 million for the fourth quarter, up from $7 ...
Hosted on MSN
MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance
Management reiterated guidance for 2025, expecting core revenue to be flat to a 10% decline compared to 2024, inclusive of SeQure DX revenue. SPL program-related revenue for 2025 is expected to be ...
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results